查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1813964

心房颤动市场规模、份额和趋势分析报告：按治疗类型、最终用途、地区和细分市场预测，2025 年至 2033 年

Atrial Fibrillation Market Size, Share & Trends Analysis Report By Treatment Type (Pharmacological Treatment, Non-pharmacological Treatment), By End-use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

心房颤动市场摘要

2024 年全球心房颤动市场价值估计为 268.9 亿美元，预计到 2033 年将达到 653.3 亿美元，2025 年至 2033 年的复合年增长率为 10.44%。

心房颤动市场的发展受到疾病负担不断增加、治疗和诊断技术的快速进步以及向远端患者监护转变的推动。

随着临床实践逐渐转向更有效率、以患者为中心的模式，能够将这些进步融入综合护理解决方案的公司有望主导市场成长。旨在扩大创新疗法可及性的策略联盟和收购可能会进一步加剧市场竞争。

由于人口老化以及高血压、糖尿病和肥胖等风险因素的增加，心房颤动的盛行率不断上升，这是推动市场成长的主要因素。心房颤动是中风和心臟衰竭的主要原因之一，医疗保健系统优先考虑早期诊断和有效管理。患者数量的增加直接增加了对药物治疗和先进介入手术的需求。 2024 年 5 月，CDC 将心房颤动 (AFib) 列为美国最常见的心律不整疾病。到 2030 年，患有心房颤动的美国人预计将增加到 1,210 万人。心房颤动每年导致约 158,000 人死亡，约七分之一的中风病例是由心房颤动引起的。

心导管电气烧灼术、3D 电解剖映射和可穿戴心电图 (ECG) 监测器等技术进步正在提高心房颤动治疗的准确性和安全性。人工智慧在心律不整检测和程序规划中的整合，使得诊断更快、更准确以及标靶治疗成为可能。这些技术进步正在将治疗选择扩展到更多患者、改善疗效并降低復发率。据心律学会 (HRS) 称，2025 年 4 月在心律 2025 大会上发表的一项新研究展示了人工智慧 (AI) 如何提高心房颤动 (AFib) 治疗的安全性和成功率。由人工智慧驱动的 DeePRISM 模型能够在消融过程中进行即时波形分析，从而改善持续性心房颤动患者的预后。专家强调了人工智慧透过提高临床可靠性和程序准确性来改变电生理学的潜力。

远端监控和远端医疗平台的采用正在改变心房颤动的管理方式，使临床环境之外的持续心律监测成为可能。穿戴式心电图设备和智慧型手机连结应用程式为患者和医生提供即时数据，支援主动管理和早期疗育。医疗保健提供者正在利用这些工具有效地监测更大的患者群体，特别是在术后追踪和长期照护方面。 2025 年 5 月，墨尔本脑中心的研究人员开发了一个人工智慧模型，能够透过分析脑部 MRI 扫描来检测中风患者中的无症状性心房颤动 (AF)。该技术在区分 AF 相关中风方面表现出很高的准确性（AUC 0.81），提供了一种非侵入性且有效的检测方法。这种方法可以透过标记需要进一步心臟评估的隐藏 AF 病例来加速诊断并个性化中风治疗。

丛集柱状图显示了1990年至2021年美洲地区与心房颤动相关的伤残调整生命年（DALY）和死亡率的增长情况。 DALY从每10万人117.14人增加到120.68人，死亡率从每10万人4.18人增加到4.84人。这反映出医疗保健系统持续承受日益增长的压力，尤其是在早期发现和获得先进治疗机会仍然不均衡的地区。如果没有针对性的医疗保健政策来缩小这些地区差异，预计未来几十年心房颤动的临床和经济负担将进一步增加。

心房颤动 (AF) 仍然是全球最常见的持续性心律不整，由于其与中风、心臟衰竭和死亡风险增加有关，对医疗保健系统构成了重大挑战。儘管治疗方法有所进步，但过去 30 年来，全球 AF 盛行率增加了一倍以上。根据《柳叶刀区域卫生美洲》2025 年 7 月的报告，区域差异继续影响着整个大陆的 AF 负担。美国的AF 发生率和盛行率最高，而加拿大的盛行率则经年龄调整后呈下降趋势。中等收入国家占 AF 病例的大多数，由于筛检基础设施有限，发病率不断上升。解决这些系统性差异对于减轻 AF 对该地区日益恶化的临床和经济影响至关重要。

目录

第一章调查方法与范围

第二章执行摘要

第三章全球心房颤动市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 补贴市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 全球心房颤动市场分析工具
    • 产业分析-波特五力分析
    • PESTLE分析
  • 技术格局
  • 案例研究分析

4. 2021-2033 年全球心房颤动市场細項分析（依治疗类型）

  • 定义和范围
  • 市占率分析：治疗类型，2024 年和 2033 年
  • 细分仪表板
  • 2021-2033年全球心房颤动治疗市场（依治疗类型）
  • 药物治疗
    • 2021-2033年药物治疗市场估计与预测
    • 抗心律不整药物
    • 抗凝血剂
  • 非药物治疗
    • 2021-2033年非药物治疗市场估计与预测
    • 心导管电气烧灼术
    • 迷宫手术
    • 电去心房颤动

5. 2021-2033 年全球心房颤动市场細項分析（依最终用途）

  • 定义和范围
  • 2024 年和 2033 年按最终用途分類的市场份额分析
  • 细分仪表板
  • 2021-2033年全球心房颤动市场（依最终用途）
  • 医院
    • 2021-2033年医院市场估计与预测
  • 专科诊所
    • 专科诊所市场估计与预测（2021-2033 年）
  • 其他的
    • 2021年至2033年其他市场估计与预测

6. 2021-2033 年心房颤动市场細項分析（按地区）

  • 2024 年及 2033 年各地区市占率分析
  • 市场仪表板：按地区
  • 市场概况：按地区
  • 2024年及2033年各地区心房颤动市占率
  • 北美洲
    • 北美心房颤动市场，2021-2033
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 2021-2033年欧洲心房颤动市场
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司分类
  • 公司简介
    • AtriCure Inc.
    • Boehringer Ingelheim GmbH
    • Boston Scientific Corporation.
    • Bristol-Myers Squibb Corporation
    • Cardio Focus Inc.
    • Sanofi Aventis
    • Biosense Webster Inc.
    • Endoscopic Technologies Inc.
    • Abbott（St. Jude Medical Inc.）
    • Johnsons &Johnson
Product Code: 978-1-68038-004-0

Atrial Fibrillation Market Summary

The global atrial fibrillation market size was estimated at USD 26.89 billion in 2024 and is projected to reach USD 65.33 billion by 2033, growing at a CAGR of 10.44% from 2025 to 2033. The atrial fibrillation market is driven by a growing disease burden, rapid technological evolution in treatment and diagnostics, and the shift toward remote patient monitoring.

Companies capable of integrating these advancements into comprehensive care solutions are likely to lead market growth as clinical practices adapt to more efficient and patient-centric models. Strategic collaborations and acquisitions aimed at expanding access to innovative therapies will further accelerate market competitiveness.

The rising prevalence of atrial fibrillation, driven by aging populations and an increase in risk factors such as hypertension, diabetes, and obesity, is a major factor driving market growth. Atrial fibrillation is one of the leading causes of stroke and heart failure, prompting healthcare systems to prioritize early diagnosis and effective management. The growing patient pool is directly increasing demand for pharmacological treatments and advanced interventional procedures. In May 2024, the CDC highlighted atrial fibrillation (AFib) as the most common heart arrhythmia treated in the U.S. The number of Americans affected by AFib is expected to rise to 12.1 million by 2030. AFib plays a role in roughly 158,000 deaths each year and contributes to about 1 in 7 stroke cases.

Technological advancements in catheter ablation, 3D electro-anatomical mapping, and wearable ECG monitors are enhancing the precision and safety of atrial fibrillation treatments. Integration of artificial intelligence in arrhythmia detection and procedural planning is enabling faster, more accurate diagnosis and targeted therapy. These innovations are expanding treatment options to more patients while improving procedural outcomes and reducing recurrence rates. In April 2025, according to the Heart Rhythm Society (HRS), new research unveiled at Heart Rhythm 2025 showcased how artificial intelligence (AI) is enhancing safety and success rates in atrial fibrillation (AFib) treatments. The AI-driven DeePRISM model enables real-time waveform analysis during ablation procedures, improving outcomes for patients with persistent AFib. Experts highlighted AI's potential to transform electrophysiology by boosting clinical confidence and procedural precision.

The adoption of remote monitoring and telehealth platforms is changing how atrial fibrillation is managed, allowing continuous rhythm monitoring beyond clinical settings. Wearable ECG devices and smartphone-linked applications are providing real-time data to both patients and physicians, supporting proactive management and early intervention. Healthcare providers are leveraging these tools to monitor larger patient populations efficiently, especially for post-procedural follow-up and long-term care. In May 2025, researchers from the Melbourne Brain Centre developed an AI model that can detect silent atrial fibrillation (AF) in stroke patients by analyzing brain MRI scans. The technology showed promising accuracy (AUC 0.81) in differentiating AF-related strokes, offering a non-invasive and efficient detection method. This approach could potentially accelerate diagnosis and personalize stroke care by flagging hidden AF cases needing further cardiac evaluation.

The clustered column chart highlights the incremental rise in atrial fibrillation-related disability-adjusted life years (DALYs) and death rates across the Americas from 1990 to 2021. DALYs increased from 117.14 to 120.68 per 100,000 and death rates rose from 4.18 to 4.84 per 100,000. This reflects a persistent and growing burden on healthcare systems, particularly in regions where access to early detection and advanced treatment remains uneven. Without targeted healthcare policies to bridge these regional disparities, the clinical and economic strain of atrial fibrillation is projected to intensify in the coming decades.

Atrial fibrillation (AF) remains the most common sustained cardiac arrhythmia worldwide, posing a substantial challenge to healthcare systems due to its association with stroke, heart failure, and elevated mortality risks. Despite advancements in treatment options, the global prevalence of AF has more than doubled over the past three decades, driven by aging populations and lifestyle-related risk factors. In July 2025, according to The Lancet Regional Health Americas, regional disparities continue to shape the burden of atrial fibrillation across the continent. The U.S. experienced the highest rise in AF incidence and prevalence, while Canada saw a decline after age adjustments. Middle-income countries account for the majority of AF cases, facing rising incidence rates with limited screening infrastructure. Addressing these systemic gaps is critical to mitigating AF's escalating clinical and economic impact in the region.

Global Atrial Fibrillation Market Report Segmentation

This report forecasts revenue growth and provides at global, regional, and country levels an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global atrial fibrillation market report based on treatment type, end-use, and region:

  • Treatment Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmacological Treatment
    • Anti-arrhythmic Drugs
    • Anticoagulant Drugs
  • Non-Pharmacological Treatment
    • Catheter Ablation
    • Radiofrequency
    • HIFU
    • Cryoablation
    • Microwave
    • Laser
    • Maze Surgery
    • Electric Cardioversion
  • End-Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Specialty Clinics
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment scope
    • 1.1.2. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. Research Assumptions
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment type outlook
    • 2.2.2. End use outlook
  • 2.3. Competitive Insights

Chapter 3. Global Atrial Fibrillation Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Global Atrial Fibrillation: Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTLE Analysis
  • 3.4. Technology Landscape
  • 3.5. Case Study Analysis

Chapter 4. Global Atrial Fibrillation Market Segment Analysis, By Treatment Type, 2021 - 2033 (USD Million)

  • 4.1. Definition and Scope
  • 4.2. Treatment Type Market Share Analysis, 2024 & 2033
  • 4.3. Segment Dashboard
  • 4.4. Global Atrial Fibrillation Market, by Treatment Type, 2021 to 2033
  • 4.5. Pharmacological Treatment
    • 4.5.1. Pharmacological treatment market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.5.2. Anti-arrhythmic Drugs
      • 4.5.2.1. Anti-arrhythmic drugs market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.5.3. Anticoagulant Drugs
      • 4.5.3.1. Anticoagulant drugs market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.6. Non-Pharmacological Treatment
    • 4.6.1. Non-pharmacological treatment market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.6.2. Catheter Ablation
      • 4.6.2.1. Catheter ablation market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.6.2.2. Radiofrequency
        • 4.6.2.2.1. Radiofrequency market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.6.2.3. HIFU
        • 4.6.2.3.1. HIFU market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.6.2.4. Cryoablation
        • 4.6.2.4.1. Cryoablation market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.6.2.5. Microwave
        • 4.6.2.5.1. Microwave market estimates and forecasts, 2021 to 2033 (USD Million)
      • 4.6.2.6. Laser
        • 4.6.2.6.1. Laser market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.6.3. Maze Surgery
      • 4.6.3.1. Maze surgery market estimates and forecasts, 2021 to 2033 (USD Million)
    • 4.6.4. Electric Cardioversion
      • 4.6.4.1. Electric cardioversion market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 5. Global Atrial Fibrillation Market Segment Analysis, By End Use, 2021 - 2033 (USD Million)

  • 5.1. Definition and Scope
  • 5.2. End Use Market Share Analysis, 2024 & 2033
  • 5.3. Segment Dashboard
  • 5.4. Global Atrial Fibrillation Market, by End Use, 2021 to 2033
  • 5.5. Hospitals
    • 5.5.1. Hospitals market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.6. Specialty Clinics
    • 5.6.1. Specialty Clinics market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 6. Atrial Fibrillation Market Segment Analysis, By Region, 2021 - 2033 (USD Million)

  • 6.1. Regional Market Share Analysis, 2024 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Regional Market Snapshot
  • 6.4. Atrial Fibrillation Market Share by Region, 2024 & 2033:
  • 6.5. North America
    • 6.5.1. North America atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.5.2. U.S.
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Scenario
      • 6.5.2.3. Competitive Scenario
      • 6.5.2.4. U.S. atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.5.3. Canada
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Scenario
      • 6.5.3.3. Competitive Scenario
      • 6.5.3.4. Canada atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.5.4. Mexico
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Scenario
      • 6.5.4.3. Competitive Scenario
      • 6.5.4.4. Mexico atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.6. Europe
    • 6.6.1. Europe atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.2. UK
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Scenario
      • 6.6.2.3. Competitive Scenario
      • 6.6.2.4. UK atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.3. Germany
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Scenario
      • 6.6.3.3. Competitive Scenario
      • 6.6.3.4. Germany atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.4. France
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Scenario
      • 6.6.4.3. Competitive Scenario
      • 6.6.4.4. France atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.5. Italy
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Scenario
      • 6.6.5.3. Competitive Scenario
      • 6.6.5.4. Italy atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.6. Spain
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Scenario
      • 6.6.6.3. Competitive Scenario
      • 6.6.6.4. Spain atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.7. Norway
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Scenario
      • 6.6.7.3. Competitive Scenario
      • 6.6.7.4. Norway atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.8. Sweden
      • 6.6.8.1. Key Country Dynamics
      • 6.6.8.2. Regulatory Scenario
      • 6.6.8.3. Competitive Scenario
      • 6.6.8.4. Sweden atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.6.9. Denmark
      • 6.6.9.1. Key Country Dynamics
      • 6.6.9.2. Regulatory Scenario
      • 6.6.9.3. Competitive Scenario
      • 6.6.9.4. Denmark atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key Country Dynamics
      • 6.7.1.2. Regulatory Scenario
      • 6.7.1.3. Competitive Scenario
      • 6.7.1.4. Japan atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Scenario
      • 6.7.2.3. Competitive Scenario
      • 6.7.2.4. China atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Scenario
      • 6.7.3.3. Competitive Scenario
      • 6.7.3.4. India atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key Country Dynamics
      • 6.7.4.2. Regulatory Scenario
      • 6.7.4.3. Competitive Scenario
      • 6.7.4.4. Australia atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key Country Dynamics
      • 6.7.5.2. Regulatory Scenario
      • 6.7.5.3. Competitive Scenario
      • 6.7.5.4. South Korea atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key Country Dynamics
      • 6.7.6.2. Regulatory Scenario
      • 6.7.6.3. Competitive Scenario
      • 6.7.6.4. Thailand atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key Country Dynamics
      • 6.8.1.2. Regulatory Scenario
      • 6.8.1.3. Competitive Scenario
      • 6.8.1.4. Brazil atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.8.2. Argentina
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Scenario
      • 6.8.2.3. Competitive Scenario
      • 6.8.2.4. Argentina atrial fibrillation market, 2021 - 2033 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key Country Dynamics
      • 6.9.1.2. Regulatory Scenario
      • 6.9.1.3. Competitive Scenario
      • 6.9.1.4. South Africa atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key Country Dynamics
      • 6.9.2.2. Regulatory Scenario
      • 6.9.2.3. Competitive Scenario
      • 6.9.2.4. Saudi Arabia atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key Country Dynamics
      • 6.9.3.2. Regulatory Scenario
      • 6.9.3.3. Competitive Scenario
      • 6.9.3.4. UAE atrial fibrillation market, 2021 - 2033 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key Country Dynamics
      • 6.9.4.2. Regulatory Scenario
      • 6.9.4.3. Competitive Scenario
      • 6.9.4.4. Kuwait atrial fibrillation market, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Profiles
    • 7.3.1. AtriCure Inc.
      • 7.3.1.1. Company overview
      • 7.3.1.2. Financial performance
      • 7.3.1.3. Product benchmarking
      • 7.3.1.4. Strategic initiatives
    • 7.3.2. Boehringer Ingelheim GmbH
      • 7.3.2.1. Company overview
      • 7.3.2.2. Financial performance
      • 7.3.2.3. Product benchmarking
      • 7.3.2.4. Strategic initiatives
    • 7.3.3. Boston Scientific Corporation.
      • 7.3.3.1. Company overview
      • 7.3.3.2. Financial performance
      • 7.3.3.3. Product benchmarking
      • 7.3.3.4. Strategic initiatives
    • 7.3.4. Bristol- Myers Squibb Corporation
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Cardio Focus Inc.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Sanofi Aventis
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Biosense Webster Inc.
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Endoscopic Technologies Inc.
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Abbott (St. Jude Medical Inc.)
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Johnsons & Johnson
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global Atrial Fibrillation Market, By Treatment Type, 2021 - 2033 (USD Million)
  • Table 4. Global Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 5. Global Atrial Fibrillation Market, By Region, 2021 - 2033 (USD Million)
  • Table 6. North America Atrial Fibrillation Market, By Country, 2021 - 2033 (USD Million)
  • Table 7. North America Atrial Fibrillation Market, By Treatment Type, 2021 - 2033 (USD Million)
  • Table 8. North America Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 9. U.S. Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 10. U.S. Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 11. Canada Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 12. Canada Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 13. Mexico Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 14. Mexico Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 15. Europe Atrial Fibrillation Market, by Country, 2021 - 2033 (USD Million)
  • Table 16. Europe Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 17. Europe Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 18. UK. Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 19. UK. Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 20. Germany Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 21. Germany Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 22. France Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 23. France Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 24. Italy Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 25. Italy Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 26. Spain Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 27. Spain Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 28. Denmark Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 29. Denmark Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 30. Sweden Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 31. Sweden Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 32. Norway Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 33. Norway Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 34. Asia Pacific Atrial Fibrillation Market, by Country, 2021 - 2033 (USD Million)
  • Table 35. Asia Pacific Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 36. Asia Pacific Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 37. Japan Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 38. Japan Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 39. China Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 40. China Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 41. India Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 42. India Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 43. Australia Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 44. Australia Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 45. Thailand Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 46. Thailand Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 47. South Korea Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 48. South Korea Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 49. Latin America Atrial Fibrillation Market, by Country, 2021 - 2033 (USD Million)
  • Table 50. Latin America Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 51. Latin America Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 52. Brazil Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 53. Brazil Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 54. Argentina Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 55. Argentina Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 56. Middle East & Africa Atrial Fibrillation Market, by Country, 2021 - 2033 (USD Million)
  • Table 57. Middle East & Africa Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 58. Middle East & Africa Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 59. South Africa Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 60. South Africa Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 61. Saudi Arabia Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 62. Saudi Arabia Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 63. UAE Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 64. UAE Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)
  • Table 65. Kuwait Atrial Fibrillation Market, by Treatment Type, 2021 - 2033 (USD Million)
  • Table 66. Kuwait Atrial Fibrillation Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Global atrial fibrillation market: outlook
  • Fig. 9 Global atrial fibrillation competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Ancillary market outlook
  • Fig. 12 Global atrial fibrillation market driver impact
  • Fig. 13 Global atrial fibrillation market restraint impact
  • Fig. 14 Porter's Analysis
  • Fig. 15 PESTLE Analysis
  • Fig. 16 Global atrial fibrillation market: Treatment type movement analysis
  • Fig. 17 Global atrial fibrillation market: Treatment type outlook and key takeaways
  • Fig. 18 Pharmacological treatment market estimates and forecast, 2021 - 2033
  • Fig. 19 Anti-arrythmic drugs market estimates and forecast, 2021 - 2033
  • Fig. 20 Anticoagulant drugs market estimates and forecast, 2021 - 2033
  • Fig. 21 Non-pharmacological treatment market estimates and forecast, 2021 - 2033
  • Fig. 22 Catheter ablation market estimates and forecast, 2021 - 2033
  • Fig. 23 Radiofrequency market estimates and forecast, 2021 - 2033
  • Fig. 24 HIFU market estimates and forecast, 2021 - 2033
  • Fig. 25 Cryoablation market estimates and forecast, 2021 - 2033
  • Fig. 26 Microwave market estimates and forecast, 2021 - 2033
  • Fig. 27 Laser market estimates and forecast, 2021 - 2033
  • Fig. 28 Maze surgery market estimates and forecast, 2021 - 2033
  • Fig. 29 Electric cardioversion market estimates and forecast, 2021 - 2033
  • Fig. 30 Global atrial fibrillation market: End use movement analysis
  • Fig. 31 Global atrial fibrillation market: End use outlook and key takeaways
  • Fig. 32 Hospitals market estimates and forecasts, 2021 - 2033
  • Fig. 33 Specialty clinics market estimates and forecasts,2021 - 2033
  • Fig. 34 Others market estimates and forecasts,2021 - 2033
  • Fig. 35 Global atrial fibrillation market: Regional movement analysis
  • Fig. 36 Global atrial fibrillation market: Regional outlook and key takeaways
  • Fig. 37 North America atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Key country dynamics
  • Fig. 39 U.S. atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 Canada atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 Mexico atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Europe atrial fibrillation market estimates and forecasts, 2021 - 2033, (USD Million)
  • Fig. 45 Key country dynamics
  • Fig. 46 UK atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 Germany atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Spain atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 France atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Italy atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Norway atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Denmark atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Sweden atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Asia Pacific atrial fibrillation market estimates and forecasts, 2021 - 2033, (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 Japan atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 China atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 India atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Australia atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 South Korea atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Thailand atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Latin America atrial fibrillation market estimates and forecasts, 2021 - 2033, (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 Brazil atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Argentina atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 79 MEA atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 South Africa atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Saudi Arabia atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 UAE atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 Kuwait atrial fibrillation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 88 Key company categorization
  • Fig. 89 Heat map analysis 2024